ClinicalTrials.gg
RecruitingNCT07194382AURA-IPFUpdated Oct 15, 2026

AURA-IPF: A Randomized Phase 2 Study to Evaluate the Safety and Efficacy of AP02 (Nintedanib Solution) in IPF

A Phase 2 interventional study of AP02 and Placebo in Idiopathic Pulmonary Fibrosis (IPF), sponsored by Avalyn Pharma Inc.. Recruiting at 49 sites in 7 countries. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2026-10-15.

Sponsored by Avalyn Pharma Inc. · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Mar 2026; still recruiting 8 months later.
Updated Oct 15, 2026First site in Turkey (Türkiye)25 sites addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
160
Allocation
Randomized
Ages
40 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 103 studies in Idiopathic Pulmonary Fibrosis with a site in United Kingdom — 14 open to participants now, 21 under way, 4 of them phase 3. Idiopathic Pulmonary Fibrosis · United Kingdom.

Planned enrollment
30th of 83
160 · median 109
Started
2026
with 8 others
Phase 2
43 of 103
9 open now
Primary completion
2026-12
later than 7 of 20 live
Registered
96th of 103
by date
Lead sponsor
2 of 103
Avalyn Pharma Inc.

Among the 103 studies in Idiopathic Pulmonary Fibrosis with a site in United Kingdom, this one is the 30th largest by planned enrollment of the 83 interventional ones that give a count, is one of 9 that started in 2026, is one of 43 in phase 2, reaches primary completion later than 7 of the 20 other live ones, and was the 96th registered.

Idiopathic Pulmonary Fibrosis

577 studies on the registry are indexed under Idiopathic Pulmonary Fibrosis; 122 are open to participants now.

Browse Idiopathic Pulmonary Fibrosis studies →

Open to participants now

14 of the 103 studies in Idiopathic Pulmonary Fibrosis with a site in United Kingdom are open now. Recruiting first, the newest first:

8 more — sign in →

All 14 open studies →

A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →

Who these studies take

Of the 84 Idiopathic Pulmonary Fibrosis studies recruiting now, 55 (65%) set no upper age limit and 7 (8%) stop at 75 or younger; 3 take children under 18; 15 take healthy volunteers.

This study: 40 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 103 studies in Idiopathic Pulmonary Fibrosis with a site in United Kingdom, or all of them as a file.
02

Study summary

This study will evaluate the impact Nintedanib Solution for Inhalation (AP02) has on lung function and key measures of fibrosis in adult patients with idiopathic pulmonary fibrosis (IPF) as well as assess its safety and tolerability.

Adults 40 years of age or older with IPF who meet the inclusion and exclusion criteria can participate in this study if they are not currently on treatment for IPF, and if treated with oral nintedanib or pirfenidone, have stopped the medication for at least 3 months.

Researchers will compare two different doses of AP02 to a placebo (a look-alike substance that contains no drug) to see if AP02 works to treat IPF. Participants are put into 1 of 3 groups randomly, which means by chance and will take AP02 or a placebo two times every day for 12 weeks by using a nebulizer, which is a device that provides medicine to the lungs via inhalation.

Participants will visit the office 6 times and receive 1 phone call over a 16-week period. At site visits doctors regularly perform breathing tests that measure how well the lungs are working, give the patient questionnaires and will check the participants' health.

03

Conditions studied

  • Idiopathic Pulmonary Fibrosis (IPF)

Keywords

  • Idiopathic Pulmonary Fibrosis
  • IPF
  • AP02
04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female patients aged ≥40 years at the time of signing the written form
  • Diagnosis of idiopathic pulmonary fibrosis (IPF) as defined by American Thoracic Society/European Respiratory Society/Japanese Respiratory Society/ Asociación Latinoamericana de Tórax IPF guidelines within 5 years
  • Combination of High-Resolution Computerized Tomography (HRCT) pattern, and if available, surgical lung pattern consistent with diagnosis of IPF
  • In a stable condition and suitable for study participation based on the results of medical history, physical examination, vital signs, 12-lead , and laboratory evaluation
  • Forced vital capacity (FVC) ≥45% predicted of normal
  • Lung diffusion test (DLCO) corrected for (Hgb) ≥30% and ≤80% predicted of normal.
  • Women and men of must use highly effective measures until 90 days after the last dose of study drug.

Exclusion criteria

Exclusion Criteria:

  • Current treatment with oral nintedanib, oral pirfenidone, or previous treatment with oral nintedanib or oral pirfenidone within 3 months prior to screening. Participants who have taken both oral nintedanib and pirfenidone together as a treatment will not be able to join the study.
  • Forced expiratory volume (FEV) in the first second/FVC (/FVC) ratio ≥0.7 based on pre-bronchodilator value
  • Participants with a history of serious cardiovascular disease, bleeding problems or significant liver or kidney disease (as defined in the study protocol)
  • History of diverticular disease or abdominal surgery within 4 weeks prior to screening visit
  • History of cancer within the past 5 years (except for certain types explained in the protocol)
  • Participants who have smoked within the past 3 months prior to screening, who are not willing to stop smoking during the study, or who currently use illegal drugs or drugs of abuse
  • Female participants who are pregnant or nursing
  • Use of any drugs including those for IPF within the past 30 days prior to screening

Further inclusion/exclusion criteria apply

Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
160 participants (estimated)

Study arms

  • Placebo comparator
    Placebo BID

    Placebo solution for Inhalation

    Drug: Placebo

  • Active comparator
    AP02 low dose BID

    Nintedanib solution for Inhalation

    Drug: AP02

  • Active comparator
    AP02 high dose BID

    Nintedanib solution for Inhalation

    Drug: AP02

Interventions

  • DrugAP02

    Oral inhalation solution

  • DrugPlacebo

    Placebo oral inhalation solution

06

What researchers measure

Primary outcomes

  1. Change from baseline in the morning pre-dose forced vital capacity at Week 12

    Time frame: From enrollment to the end of treatment at 12 weeks

Secondary outcomes

  1. Time to disease progression

    Disease progression is defined as forced vital capacity (FVC) percent predicted decline of ≥10% prior to Week 12, respiratory hospitalization, or death.

    Time frame: From enrollment to the end of treatment at 12 weeks

  2. To evaluate the change from baseline in quantitative lung fibrosis score

    Change in lung fibrosis score.

    Time frame: From enrollment to the end of treatment at 12 weeks

07

Study locations

49 of 49 sites recruiting
  • Royal Prince Alfred Hospital
    Camperdown, New South Wales, Australia
    Recruiting
  • Nepean Lung and Sleep
    Kingswood, New South Wales 2747, Australia
    Recruiting
  • John Hunter Hospital
    New Lambton Heights, New South Wales, Australia
    Recruiting
  • Macquarie University Hospital
    Sydney, New South Wales, Australia
    Recruiting
  • Ludwig Engel Centre for Respiratory Research
    Westmead, New South Wales 2145, Australia
    Recruiting
  • Launceston Respiratory and Sleep Centre
    Launceston, Tasmania, Australia
    Recruiting
  • Austin Health
    Heidelberg, Victoria, Australia
    Recruiting
  • The Alfred Hospital
    Melbourne, Victoria, Australia
    Recruiting
  • University of Calgary - Foothills Medical Centre
    Calgary, Alberta, Canada
    Recruiting
  • Centre for Lung Health - Vancouver General Hospital
    Vancouver, British Columbia, Canada
    Recruiting
  • Newfoundland and Labrador Health Services
    St. John's, Newfoundland and Labrador, Canada
    Recruiting
  • Queen Elizabeth
    Halifax, Nova Scotia, Canada
    Recruiting
  • Dynamic Drug Advancement
    Ajax, Ontario L1S2J5, Canada
    Recruiting
  • University Health Network - Toronto General Hospital
    Toronto, Ontario, Canada
    Recruiting
  • Centre Hospitalier de l'Université de Montréal (CHUM)
    Montreal, Quebec, Canada
    Recruiting
  • Jewish General Hospital
    Montreal, Quebec, Canada
    Recruiting
  • Centre Hospitalier Universitaire de Sherbrooke (CHUS) - Hôpital Fleurimont
    Sherbrooke, Quebec, Canada
    Recruiting
  • CIC Mauricie
    Trois-Rivières, Quebec G8T 7A1, Canada
    Recruiting
  • Pneumologisches Studienzentrum München-West
    Munich, Bavaria, Germany
    Recruiting
  • Studienzentrum Dr. Keller
    Frankfurt am Main, Hesse, Germany
    Recruiting
  • Universitätsklinikum Heidelberg - Thoraxklinik Heidelberg
    Heidelberg, Germany
    Recruiting
  • Universitätsmedizin der Johannes Gutenberg-Universität Mainz
    Mainz, Germany
    Recruiting
  • Christchurch Hospital
    Christchurch, Cantebury, New Zealand
    Recruiting
  • Waikato Hospital
    Hamilton, Waikato Region, New Zealand
    Recruiting
    • Sandra Hopping · Contact
  • Greenlane Clinical Centre
    Auckland, New Zealand
    Recruiting
  • Hospital Germans Trias i Pujol/Hospital Can Ruti
    Badalona, Barcelona, Spain
    Recruiting
  • Hospital General de Granollers, Barcelona
    Granollers, Barcelona, Spain
    Recruiting
  • Hospital Universitario Marqués de Valdecilla
    Santander, Cantabria, Spain
    Recruiting
  • Hospital Universitario de Bellvitge
    L'Hospitalet de Llobregat, Catalonia / Barcelona, Spain
    Recruiting
  • Consorci Corporació Sanitària Parc Taulí (Parc Taulí Hospital Universitari)
    Sabadell, Catalonia / Barcelona, Spain
    Recruiting
  • Hospital Clínic de Barcelona
    Barcelona, Spain
    Recruiting
  • Hospital HM Sanchinarro
    Madrid, Spain
    Recruiting
  • Hospital Universitario de la Princesa
    Madrid, Spain
    Recruiting
  • Hospital Universitario Virgen de la Victoria
    Málaga, Spain
    Recruiting
  • Istanbul University Cerrahpasa Hospital
    Istanbul, Turkey (Türkiye)
    Recruiting
  • Gülhane Saglik Bilimleri Fakültesi
    Keçiören, Turkey (Türkiye)
    Recruiting
  • Royal Devon University Hospital
    Exeter, Devon, United Kingdom
    Recruiting
  • Hull University Hospitals NHS Trust
    Cottingham, East Riding of Yorkshire, United Kingdom
    Recruiting
  • Leicester Biomedical Research Centre
    Leicester, Leicestershire, United Kingdom
    Recruiting
  • University Hospitals Birmingham NHS Foundation Trust
    Birmingham, West Midlands, United Kingdom
    Recruiting
  • University Hospitals Birmingham NHS Foundation Trust - Heartlands Hospital
    Birmingham, United Kingdom
    Recruiting
  • Royal Papworth Hospital NHS Foundation Trust
    Cambridge, United Kingdom
    Recruiting
  • Aintree University Hospital
    Liverpool, United Kingdom
    Recruiting
  • Royal Brompton Hospital, Guy's and St Thomas NHS Foundation Trust
    London, United Kingdom
    Recruiting
  • St. George's University Hospitals NHS Foundation Trust
    London, United Kingdom
    Recruiting
  • Altnagelvin Hospital Campus
    Londonderry, United Kingdom
    Recruiting
  • Manchester University NHS Foundation Trust - NIHR Manchester Clinical Research Facility at Wythenshawe Hospital
    Manchester, United Kingdom
    Recruiting
  • Oxford University Hospitals NHS Foundation Trust - Churchill Hospital
    Oxford, United Kingdom
    Recruiting
  • NHS Tayside - Perth Royal Infirmiry (Scotland)
    Perth, United Kingdom
    Recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2026 (actual). Primary completion is estimated for Dec 2026, 9 months after the start.

Of 63 industry-sponsored phase 2 interventional studies under Idiopathic Pulmonary Fibrosis, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 45. This study's planned 9 months is below that.

Counting every sponsor, half of 76 studies reached it within 29 months; a quarter within 21 and three quarters within 50.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 4, 2025
First posted
Sep 26, 2025
StartActual
Mar 10, 2026
Primary completionEst.
Dec 2026
CompletionEst.
Jun 2027
Last update
Oct 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
25 sites added — first site in Turkey (Türkiye)
Show 25 added (9 United Kingdom, 5 Australia, 4 Canada, 3 Spain, 2 Germany, 2 Turkey (Türkiye))
  • John Hunter Hospital · New Lambton Heights, Australia
  • Macquarie University Hospital · Sydney, Australia
  • Launceston Respiratory and Sleep Centre · Launceston, Australia
  • Austin Health · Heidelberg, Australia
  • The Alfred Hospital · Melbourne, Australia
  • University of Calgary - Foothills Medical Centre · Calgary, Canada
  • University Health Network - Toronto General Hospital · Toronto, Canada
  • Jewish General Hospital · Montreal, Canada
  • Centre Hospitalier Universitaire de Sherbrooke (CHUS) - Hôpital Fleurimont · Sherbrooke, Canada
  • Universitätsklinikum Heidelberg - Thoraxklinik Heidelberg · Heidelberg, Germany
  • Universitätsmedizin der Johannes Gutenberg-Universität Mainz · Mainz, Germany
  • Hospital Universitario de Bellvitge · L'Hospitalet de Llobregat, Spain
  • Consorci Corporació Sanitària Parc Taulí (Parc Taulí Hospital Universitari) · Sabadell, Spain
  • Hospital Universitario de la Princesa · Madrid, Spain
  • Istanbul University Cerrahpasa Hospital · Istanbul, Turkey (Türkiye)
  • Gülhane Saglik Bilimleri Fakültesi · Keçiören, Turkey (Türkiye)
  • University Hospitals Birmingham NHS Foundation Trust - Heartlands Hospital · Birmingham, United Kingdom
  • Royal Papworth Hospital NHS Foundation Trust · Cambridge, United Kingdom
  • Aintree University Hospital · Liverpool, United Kingdom
  • Royal Brompton Hospital, Guy's and St Thomas NHS Foundation Trust · London, United Kingdom
  • St. George's University Hospitals NHS Foundation Trust · London, United Kingdom
  • Altnagelvin Hospital Campus · Londonderry, United Kingdom
  • Manchester University NHS Foundation Trust - NIHR Manchester Clinical Research Facility at Wythenshawe Hospital · Manchester, United Kingdom
  • Oxford University Hospitals NHS Foundation Trust - Churchill Hospital · Oxford, United Kingdom
  • NHS Tayside - Perth Royal Infirmiry (Scotland) · Perth, United Kingdom
Oct 15, 2026
Show all 1 update
  1. Oct 15, 2026
    25 sites added — first site in Turkey (Türkiye)
    Show 25 added (9 United Kingdom, 5 Australia, 4 Canada, 3 Spain, 2 Germany, 2 Turkey (Türkiye))
    • John Hunter Hospital · New Lambton Heights, Australia
    • Macquarie University Hospital · Sydney, Australia
    • Launceston Respiratory and Sleep Centre · Launceston, Australia
    • Austin Health · Heidelberg, Australia
    • The Alfred Hospital · Melbourne, Australia
    • University of Calgary - Foothills Medical Centre · Calgary, Canada
    • University Health Network - Toronto General Hospital · Toronto, Canada
    • Jewish General Hospital · Montreal, Canada
    • Centre Hospitalier Universitaire de Sherbrooke (CHUS) - Hôpital Fleurimont · Sherbrooke, Canada
    • Universitätsklinikum Heidelberg - Thoraxklinik Heidelberg · Heidelberg, Germany
    • Universitätsmedizin der Johannes Gutenberg-Universität Mainz · Mainz, Germany
    • Hospital Universitario de Bellvitge · L'Hospitalet de Llobregat, Spain
    • Consorci Corporació Sanitària Parc Taulí (Parc Taulí Hospital Universitari) · Sabadell, Spain
    • Hospital Universitario de la Princesa · Madrid, Spain
    • Istanbul University Cerrahpasa Hospital · Istanbul, Turkey (Türkiye)
    • Gülhane Saglik Bilimleri Fakültesi · Keçiören, Turkey (Türkiye)
    • University Hospitals Birmingham NHS Foundation Trust - Heartlands Hospital · Birmingham, United Kingdom
    • Royal Papworth Hospital NHS Foundation Trust · Cambridge, United Kingdom
    • Aintree University Hospital · Liverpool, United Kingdom
    • Royal Brompton Hospital, Guy's and St Thomas NHS Foundation Trust · London, United Kingdom
    • St. George's University Hospitals NHS Foundation Trust · London, United Kingdom
    • Altnagelvin Hospital Campus · Londonderry, United Kingdom
    • Manchester University NHS Foundation Trust - NIHR Manchester Clinical Research Facility at Wythenshawe Hospital · Manchester, United Kingdom
    • Oxford University Hospitals NHS Foundation Trust - Churchill Hospital · Oxford, United Kingdom
    • NHS Tayside - Perth Royal Infirmiry (Scotland) · Perth, United Kingdom

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07194382
Lead sponsor
Avalyn Pharma Inc.
Responsible party
Sponsor
First posted
Sep 26, 2025
Start date
Mar 10, 2026
Primary completion
Dec 2026 (estimated)
Completion
Jun 2027 (estimated)
Last update
Oct 15, 2026

Study contacts

Craig S Conoscenti, MD, FCCP, ATSF
Contact
AP02-003regulatory@avalynpharma.com
206-707-0340

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion